Limits...
A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges.

Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S - Int J Appl Basic Med Res (2015 Jan-Apr)

Bottom Line: Further, these two enzyme levels were also significantly lower in CKD patients with ESRD compared to CKD patients without the condition.Serum ALP levels were significantly higher in patients with and without ESRD as compared to the controls.Thus, the study established the need for separate reference ranges of serum aminotransferase in different stages of CKD.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Pondicherry Institute of Medical Sciences, Puducherry, India.

ABSTRACT

Background: Hepatic diseases are common among chronic kidney disease patients and liver function tests particularly serum liver enzymes play an important role in diagnosing and monitoring these patients. Serum aminotransferase levels commonly fall near the lower end of the range of the normal values in patients of chronic kidney disease (CKD). High-levels of serum alkaline phosphatase (ALP) can occur in these patients due to renal osteodystrophy. Thus, the recognition of liver damage in these patients is challenging.

Aim: To compare the levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and ALP among three groups - CKD patients without end stage renal disease (ESRD), patients with ESRD and healthy controls.

Materials and methods: A retrospective, hospital-based study was carried out from 100 patients' records from each group and serum AST, ALT and ALP values were noted.

Results: Our study showed that serum AST and ALT levels were significantly lower in CKD patients both without and with ESRD compared to controls. Further, these two enzyme levels were also significantly lower in CKD patients with ESRD compared to CKD patients without the condition. Serum ALP levels were significantly higher in patients with and without ESRD as compared to the controls. However, the values did not differ significantly between patients with and without ESRD.

Conclusion: Levels of serum aminotransferases were low in CKD with and without ESRD and the levels become lower as the severity of CKD increases. Thus, the study established the need for separate reference ranges of serum aminotransferase in different stages of CKD.

No MeSH data available.


Related in: MedlinePlus

The values are expressed as the means ± standard deviation for the number of cases (n) in each group of subjects. Statistical comparisons were made by one way ANOVA followed by post-hoc analysis as described in the methods. *: P < 0.001 versus Group C (controls), φ: P < 0.001 versus Group B (chronic kidney disease [CKD] with end stage renal disease [ESRD]), ψ: P = 0.02, no statistically significant difference in alkaline phosphatase levels between Group A (CKD without ESRD) and Group B, P = 1.00
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4318098&req=5

Figure 1: The values are expressed as the means ± standard deviation for the number of cases (n) in each group of subjects. Statistical comparisons were made by one way ANOVA followed by post-hoc analysis as described in the methods. *: P < 0.001 versus Group C (controls), φ: P < 0.001 versus Group B (chronic kidney disease [CKD] with end stage renal disease [ESRD]), ψ: P = 0.02, no statistically significant difference in alkaline phosphatase levels between Group A (CKD without ESRD) and Group B, P = 1.00

Mentions: The statistical analysis of serum AST, ALT and ALP levels among the three study groups is shown in Figure 1. AST levels were significantly lower in both Group A (18.48 ± 4.14) and Group B (10.08 ± 3.49) as compared to controls in Group C (30.5 ± 10.75), (P < 0.001). There was also a statistically significant lowering of serum AST levels in patients belonging Group B as compared to patients in Group A (P < 0.001). Similarly serum ALT levels [Figure 1] were also significantly lower in both Group A (16.82 ± 4.38) and Group B (8.3 ± 3.58) as compared to Group C (26.94 ± 13.07) (P < 0.001).


A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges.

Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S - Int J Appl Basic Med Res (2015 Jan-Apr)

The values are expressed as the means ± standard deviation for the number of cases (n) in each group of subjects. Statistical comparisons were made by one way ANOVA followed by post-hoc analysis as described in the methods. *: P < 0.001 versus Group C (controls), φ: P < 0.001 versus Group B (chronic kidney disease [CKD] with end stage renal disease [ESRD]), ψ: P = 0.02, no statistically significant difference in alkaline phosphatase levels between Group A (CKD without ESRD) and Group B, P = 1.00
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4318098&req=5

Figure 1: The values are expressed as the means ± standard deviation for the number of cases (n) in each group of subjects. Statistical comparisons were made by one way ANOVA followed by post-hoc analysis as described in the methods. *: P < 0.001 versus Group C (controls), φ: P < 0.001 versus Group B (chronic kidney disease [CKD] with end stage renal disease [ESRD]), ψ: P = 0.02, no statistically significant difference in alkaline phosphatase levels between Group A (CKD without ESRD) and Group B, P = 1.00
Mentions: The statistical analysis of serum AST, ALT and ALP levels among the three study groups is shown in Figure 1. AST levels were significantly lower in both Group A (18.48 ± 4.14) and Group B (10.08 ± 3.49) as compared to controls in Group C (30.5 ± 10.75), (P < 0.001). There was also a statistically significant lowering of serum AST levels in patients belonging Group B as compared to patients in Group A (P < 0.001). Similarly serum ALT levels [Figure 1] were also significantly lower in both Group A (16.82 ± 4.38) and Group B (8.3 ± 3.58) as compared to Group C (26.94 ± 13.07) (P < 0.001).

Bottom Line: Further, these two enzyme levels were also significantly lower in CKD patients with ESRD compared to CKD patients without the condition.Serum ALP levels were significantly higher in patients with and without ESRD as compared to the controls.Thus, the study established the need for separate reference ranges of serum aminotransferase in different stages of CKD.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Pondicherry Institute of Medical Sciences, Puducherry, India.

ABSTRACT

Background: Hepatic diseases are common among chronic kidney disease patients and liver function tests particularly serum liver enzymes play an important role in diagnosing and monitoring these patients. Serum aminotransferase levels commonly fall near the lower end of the range of the normal values in patients of chronic kidney disease (CKD). High-levels of serum alkaline phosphatase (ALP) can occur in these patients due to renal osteodystrophy. Thus, the recognition of liver damage in these patients is challenging.

Aim: To compare the levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and ALP among three groups - CKD patients without end stage renal disease (ESRD), patients with ESRD and healthy controls.

Materials and methods: A retrospective, hospital-based study was carried out from 100 patients' records from each group and serum AST, ALT and ALP values were noted.

Results: Our study showed that serum AST and ALT levels were significantly lower in CKD patients both without and with ESRD compared to controls. Further, these two enzyme levels were also significantly lower in CKD patients with ESRD compared to CKD patients without the condition. Serum ALP levels were significantly higher in patients with and without ESRD as compared to the controls. However, the values did not differ significantly between patients with and without ESRD.

Conclusion: Levels of serum aminotransferases were low in CKD with and without ESRD and the levels become lower as the severity of CKD increases. Thus, the study established the need for separate reference ranges of serum aminotransferase in different stages of CKD.

No MeSH data available.


Related in: MedlinePlus